AC Immune (NASDAQ:ACIU) Stock Rating Upgraded by Wall Street Zen

AC Immune (NASDAQ:ACIU) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Several other analysts have also issued reports on the stock. BTIG Research restated a “buy” rating and issued a $8.00 price target on shares of AC Immune in a research report on Tuesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of AC Immune in a research report on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, AC Immune currently has a consensus rating of “Hold” and a consensus target price of $10.00.

AC Immune Stock Down 1.0%

Shares of NASDAQ ACIU opened at $2.93 on Friday. AC Immune has a 12 month low of $1.43 and a 12 month high of $4.00. The company has a market cap of $294.20 million, a P/E ratio of -3.49 and a beta of 1.66. The business’s 50 day moving average is $3.20 and its two-hundred day moving average is $2.96.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ACIU. Assenagon Asset Management S.A. acquired a new stake in shares of AC Immune in the 3rd quarter valued at $549,000. Marshall Wace LLP acquired a new position in AC Immune in the fourth quarter valued at about $586,000. Acadian Asset Management LLC boosted its position in AC Immune by 87.1% in the first quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock valued at $679,000 after buying an additional 172,796 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of AC Immune by 20.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 213,464 shares of the company’s stock valued at $670,000 after acquiring an additional 36,353 shares during the last quarter. Finally, Sei Investments Co. acquired a new position in shares of AC Immune in the 2nd quarter worth approximately $51,000. 51.36% of the stock is currently owned by institutional investors and hedge funds.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.